It is Frontotemporal Dementia Awareness Week. OHE is contributing to the PREDICT-FTD consortium, which aims to advance a biomarker-based diagnosis of frontotemporal dementia. www.ohe.org/insights/the-true-cost-and-burden-of-frontotemporal-dementia-early-insights-into-a-pressing-challenge/

The NHS 10 Year Health Plan puts prevention at the centre. Misaligned incentives, behavioural barriers, and risks of widening inequalities raise the question: can prevention truly move from ambition to action? Find out: www.ohe.org/insights/pre...

China’s evolving HTA system is transforming access to medicines for 1.4B people. 700+ drugs added to the NRDL since 2017, but there are still challenges like transparency and data gaps. Read the insight:

Climate action is health action. Health economics can help shape smarter, fairer decisions – from green #HTA to valuing co-benefits of #climatepolicy. www.ohe.org/insights/cli...

What is STRIDES? A new #framework to capture the full value of #AMR diagnostics in tackling #antimicrobial resistance. Read more on how #diagnostics can help fight AMR: www.ohe.org/insights/fro...

How can we use health economics to inform climate-related policy without needing new frameworks? 📆 8 July 2025 🕛 10:00 BST 📍 Virtual event Register here: www.ohe.org/events/valui... #healtheconomics #climatechange #sustainability #publichealth

Health reforms in the Middle East are bold, fast, and values-driven. #HTA, workforce, and #pricing models are being reimagined, read our insight on what this means for #healtheconomists: www.ohe.org/insight/heal...

There is a range of ways ex-US payers and pharma companies might respond to President Trump’s “Most Favoured Nation” drug pricing. Will any of them work to lower #US drug prices? Read more: www.ohe.org/insight/the-trump-administrations-us-drug-pricing-proposal-what-will-happen-next/

New insight: 68% of OECD countries formally use #QALYs in pricing decisions, but practices vary. How consistent is economic evaluation across borders? www.ohe.org/insight/how-... #HTA #healtheconomics

New report on STRIDES—a framework to better value AMR #diagnostics. #Diagnostics are key to tackling #AMR, but #policy still overlooks their impact. Read more: www.ohe.org/publications...

Argentina plans a new national #HTA agency, ANEFiTS. A big step for evidence-based #policy, but key questions on governance, transparency & legal power remain. Read more: www.ohe.org/insight/arou...

New insight: a substantial proportion of these medicines do not deliver their intended therapeutic benefits for the individuals taking them, due to genetic variations. ##pharmacogenomics #CERSI www.ohe.org/insight/pharmacogenomics-testing-a-crucial-piece-to-unlocking-the-full-value-of-medicines/

Vaccines return up to 19x their cost, but adult #immunisation is undervalued. Our new insight calls for long-term investment to boost health, productivity & system resilience. www.ohe.org/insight/prevention-pays-off-so-why-arent-we-doing-more-of-it/

President Trump says the rest of the world “free rides” on the #US – and wants to peg US #drugprices to other countries’. This isn’t a new idea – but what might be different with his latest Executive Order? Read more: www.ohe.org/insight/the-...

New OHE report: Europe is off-track to meet 2030 #HIV eradication targets. Rising diagnoses, late testing & mounting costs demand urgent action. We highlight key barriers, the cost of complacency & solutions. Read more: www.ohe.org/publications... #publichealth #healtheconomics

How can the #UK prepare for an #ageingsociety? OHE’s submission to a #parliamentary inquiry stressed that keeping as many people as healthy and productive as possible – for as long as possible – is a requisite measure in addressing a shrinking #workforce. Read more: www.ohe.org/insight/offi...

Kenya is making progress on using evidence to guide healthcare decisions. New reforms embed #HTA in #policy, but challenges in capacity, funding and transparency remain. www.ohe.org/insight/arou...

Andy Briggs, presenting at #ISPORMontreal on whether we should be ‘greening’ our HTA methods in a panel organised by @ohenews.bsky.social on Environmental Sustainability and Whole Health. You can read the write up of his presentation on occamresearch.substack.com/p/greening-hta

"The Price Effects of Biosimilars In the US" by Mireia Jofre-Bonet et al. concludes the US biosimilars market has become highly competitive; driving price reductions between 2015-2023 with substantial savings for Medicare ➡️ tinyurl.com/PriceEffects... @ohenews.bsky.social #HealthEconomics

GLP-1s are changing #obesity care—but access, equity, and patient preferences raise new challenges. Our latest insight looks at what this means for #policy and practice. www.ohe.org/insight/glp-... #healtheconomics #GLP1

📢 New publication from OHE: Understanding the full value of long-acting therapies: Less is more? We will also be discussing this research at ISPOR 2025 in Issue Panel 116. Join us for the discussion! Read it here: www.ohe.org/publications... #healtheconomics #HTA

47% of NICE “positive” decisions now limit treatment to just 31% of eligible patients. A new OHE report looks at the rise in ‘optimised’ guidance—and what it means for patient access. www.ohe.org/publications... #HTA

Respiratory infections can cost UK businesses £44 billion a year—but how much is your company losing? Use the new Cost Calculator from OHE & funded and owned by Pfizer to get a tailored estimate and consider the impact on productivity. Try it now: www.ohe.org/respiratory-... #HealthEconomics

A good read for anyone working with EQ-5D or cognitive outcomes 👀 New research by Hannah Hussain (OHE) underlines EuroQol's current bolt-on development. Results like this will affect how we assess HRQoL in dementia, mental health, and other diseases where cognitive impairment plays a pivotal role.

From the Archives: Our report, published at April 2024, looked at how HTA methods have evolved across 14 countries, highlighting key reforms, guidance gaps, and the role of international collaboration in shaping future approaches. Find out more: www.ohe.org/publications... #HTA #healtheconomics

New report: Analysing Global Immunisation Expenditure Immunisation is critical for public health, but funding remains low. Our latest report reveals key trends in investment, preventable mortality & coverage. www.ohe.org/publications... #Immunisation #PublicHealth #HealthEconomics #Vaccines

The adoption of a societal perspective in HTA can help addressing societal and economic needs in the Asian-Pacific region, but its implementation is limited. Barriers include the lack of methods and evidence and capacity constraints. #HTA #HealthEconomics

Should cognition be added to EQ-5D? New research by OHE's Hannah Hussain explores whether memory & concentration perform better than a single “cognition” item. Findings could reshape EQ-5D use in dementia, mental health & HTA. www.ohe.org/insight/addi...

Canada’s HTA system blends provincial autonomy with national coordination. CDA-AMC’s evolving role and the pan-Canadian Pharmaceutical Alliance are reshaping drug access and pricing. Future reforms, including national Pharmacare and global collaboration, promise more efficient and patient access.

HTA plays a key role in patient access and healthcare investments. Our Around the World in HTAs series analyses how different countries assess new treatments, the growing influence of international collaboration, and why stakeholder engagement matters. #healthtecth #healtheconomics #hta

Learn about Hidradenitis Suppurativa (HS) – a chronic skin disease affecting 200K+ people in the UK. Some of the challenges people living with HS include mental health, financial costs, impact on relationships. #HidradenitisSuppurativa

📸 Here are some photos of Prof Briggs on his big award day with @ohenews.bsky.social Prof Briggs received the 2024 OHE Innovation Policy Prize for his plan to incentivise innovation in the life sciences sector in an environmentally sustainable way Read more in our article 🔽

Can diversity of supply in #raredisease markets improve patients’ health and health system efficiency?